Related Experiment Video
Updated: Mar 11, 2026
Author Spotlight: Integrating High-Resolution Intravital Imaging and MRI to Enhance Stereotactic Body Radiation Therapy Planning
Published on: April 12, 2024
Molecular Imaging and Precision Medicine in Head and Neck Cancer
Esther Mena1, Shwetha Thippsandra1, Anusha Yanamadala1
1Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Johns Hopkins University, 601 North Caroline Street, Baltimore, MD 21287, USA.
Abstract:
The concept of using tumor genomic profiling information has revolutionized personalized cancer treatment. Head and neck (HN) cancer management is being influenced by recent discoveries of activating mutations in epidermal growth factor receptor and related targeted therapies with tyrosine kinase inhibitors, targeted therapies for Kristen Rat Sarcoma, and MET proto-oncogenes. Molecular imaging using PET plays an important role in assessing the biologic behavior of HN cancer with the goal of delivering individualized cancer treatment. This review summarizes recent genomic discoveries in HN cancer and their implications for functional PET imaging in assessing response to targeted therapies, and drug resistance mechanisms.
Insights
Tumor genomic profiling transforms head and neck (HN) cancer care. This review explores genomic discoveries and their impact on PET imaging for targeted therapy response and resistance.
Area of Science:
- Oncology
- Molecular Imaging
- Genomics
Background:
- Personalized cancer treatment is increasingly driven by tumor genomic profiling.
- Head and neck (HN) cancers are seeing advancements through targeted therapies based on genetic mutations.
- Molecular imaging, particularly PET, is crucial for understanding HN cancer biology and guiding treatment.
Purpose of the Study:
- To review recent genomic discoveries in HN cancer.
- To discuss the implications of these discoveries for functional PET imaging.
- To explore how PET can assess response to targeted therapies and identify drug resistance.
Main Methods:
- Literature review of recent genomic discoveries in HN cancer.
- Analysis of the role of molecular imaging (PET) in assessing targeted therapy response.
- Examination of mechanisms of drug resistance in HN cancer.
Main Results:
- Identification of key activating mutations (e.g., EGFR, KRAS, MET) influencing HN cancer.
- Demonstration of PET's utility in evaluating biological changes in response to targeted agents.
- Insights into how genomic alterations affect treatment outcomes and resistance.
Conclusions:
- Genomic profiling is revolutionizing HN cancer management.
- Functional PET imaging holds significant potential for monitoring targeted therapy efficacy.
- Understanding genomic alterations is key to overcoming drug resistance in HN cancer.
